We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Reducing N-Cadherin Increases Survival in Mouse Model of Pancreatic Cancer

By LabMedica International staff writers
Posted on 11 Jan 2012
Reduction in the activity of a key membrane adhesive protein causes pancreatic cancer cells to lose the ability to metastasize and spread tumors to other sites within the body.

Pancreatic ductal adenocarcinma (PDA) does not typically produce symptoms until after it has metastasized. More...
Late detection leads to a high mortality rate with a five-year survival rate of less than 5%.

Investigators at Thomas Jefferson University (Philadelphia, PA, USA) worked with lines of genetically engineered mice to determine whether modifying PDA cell surface proteins could block the ability of the cancer to spread.

They reported in the December 12, 2011, online edition of the journal Oncogene that mice with reduced N-cadherin expression survived 25% longer than animals expressing two wild-type N-cadherin (Cdh2) alleles.

Cadherins are members of a family of calcium-dependent cell adhesion proteins that preferentially interact in a homophilic manner in cell-cell interactions. They are type I membrane proteins that contribute to the sorting of heterogeneous cell types. The names of different classes indicate the tissues in which they were first found: E-cadherin is present on many types of epithelial cells; N-cadherin is present on nerve, muscle, and lens cells; and P-cadherin is present on placental and epidermal cells. Typically, cadherins have five similar extracellular domains, the outermost three of which have Ca2+-binding sites, and an intracellular C-terminal domain that interacts with the actin cytoskeleton.

“Previous studies demonstrated the importance of this cell surface protein for tumor cell growth,” said senior author Dr. Glenn Radice, associate professor of medicine at Thomas Jefferson University. “However, it was not clear from those studies whether interfering with N-cadherin levels would increase survival of animals genetically engineered to develop highly metastatic pancreatic cancer. Our survival results are very exciting because a drug, known as ADH-1that specifically targets N-cadherin is already in clinical trial for melanoma. The next step is to test this N-cadherin-function blocking drug or a similar compound in the pancreatic cancer mouse model to see if it can prolong survival.”

Related Links:

Thomas Jefferson University




Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A simple blood sample that allows DNA methylation could identify epigenetic biomarkers (Photo courtesy of 123RF)

Simple Blood Sample Could Identify Epigenetic Biomarkers to Predict CVD Risk in Type 2 Diabetes

People with type 2 diabetes face up to four times higher risk of cardiovascular events such as heart attacks, strokes, and angina compared to individuals without the condition. Yet, current tools used... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The new technology could predict who will benefit from immunotherapy (Photo courtesy of Max Delbrück Center)

New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response

A healthy immune system depends on complex communication between specialized cell types that detect, alert, and eliminate harmful threats. When these immune signaling pathways break down, the result can... Read more

Microbiology

view channel
Image: MycoMEIA Aspergillus Assay is the first FDA-cleared urine-based test for invasive aspergillosis (Photo courtesy of Pearl Diagnostics)

Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People

Invasive Aspergillosis (IA), a life-threatening fungal infection, poses a serious threat to immunocompromised individuals, especially those with hematologic malignancies, transplants, or severe lung diseases.... Read more

Industry

view channel
Image: The acquisition of Exosome Diagnostics adds the ExoDx Prostate test to Mdxhealth’s portfolio (Photo courtesy of Bio-Techne)

Bio-Techne Divests Exosome Diagnostics to Reposition Product Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has entered into an agreement with Mdxhealth SA (Irvine, CA, USA), which will acquire its Exosome Diagnostics Inc. (Waltham, MA, US) business, including the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.